Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Sint-Martens-Latem – page 22

1 432 clinical trials in Sint-Martens-Latem, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Sint-Martens-Latem at a glance
1 432
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 432 trials in Sint-Martens-Latem

Open in trial search

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ficerafusp alfa
  • Sponsor:Bicara Therapeutics Inc.

Study of SAR444336 in Adults with Microscopic Colitis Who Achieved Clinical Remission with Budesonide Treatment

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:SAR444336
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Safety and Tolerability Study of NBI-1065845 as Additional Treatment for Adults with Major Depressive Disorder

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Osavampator
  • Sponsor:Neurocrine Biosciences Inc.

IgA nephropathy

Recruiting

Study of felzartamab compared to placebo in adults with IgA nephropathy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Biogen Idec Research Limited

Study of MK-2214 to slow disease progression in people with early Alzheimer's disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Florquinitau (18F)
  • Sponsor:Merck Sharp & Dohme LLC

Evaluating Hyperbaric Oxygen Treatment in Addition to Standard Care for Patients with Necrotizing Soft-Tissue Infection

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Oxygen
  • Sponsor:Region Hovedstaden

Study of zolbetuximab combined with paclitaxel and ramucirumab for patients with previously treated CLDN18.

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zolbetuximab
  • Sponsor:UZ Leuven

Study of telisotuzumab adizutecan with osimertinib as first treatment for adults with advanced or metastatic EGFR-mutated non-small cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Atacicept Treatment for Patients with Multiple Autoimmune Glomerular Diseases

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Atacicept
  • Sponsor:Vera Therapeutics Inc.

Study of plozasiran to prevent acute pancreatitis in adults with severe hypertriglyceridemia

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Comparing rifampin-free treatment versus rifampin in adults with staphylococcal prosthetic valve endocarditis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cefazolin Sodium
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Sint-Martens-Latem

What the registry says about research in the country

01 Musculoskeletal Diseases

Clinical research in Sint-Martens-Latem is focused on musculoskeletal diseases, with a strong emphasis on osteoarthritis and related joint pain. The studies are designed to better understand treatment options that may improve comfort and day-to-day function.

  • Knee osteoarthritis
  • Osteoarthritis
  • Testing new approaches to ease joint pain and support mobility

These trials aim to assess whether emerging therapies can offer meaningful relief for people living with chronic joint disease.

02 Nutritional and Metabolic Diseases

Another active area is nutritional and metabolic diseases, especially studies involving overweight and obesity. Research here is exploring whether new treatments can help with weight management while also addressing related health concerns.

  • Overweight or obesity
  • Evaluating therapies that may support healthier body weight
  • Looking at how metabolic treatment options may affect symptoms linked to joint disease

In addition to weight-related outcomes, the research also considers how these approaches may influence overall well-being in people with overlapping conditions.

03 Combined Osteoarthritis and Weight-Related Research

The clinical trial landscape also brings together osteoarthritis and obesity research, reflecting the close connection between excess body weight and knee pain. This combined focus is especially relevant for patients whose symptoms are affected by both joint and metabolic factors.

  • Knee osteoarthritis with overweight or obesity
  • Measuring changes in pain and physical comfort
  • Assessing whether a new therapy can support both symptom relief and weight-related outcomes

These studies aim to generate practical evidence on treatments that may address more than one aspect of the condition at the same time.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.